You are here

Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

Last updated on April 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511-5473 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Heart Valve Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- >=18 years of age subjects with stable concomitant diseases with BMI >=30 kg/m2

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant females

- Those with unstable/new onset diseases

- Those who are on agents known to be associated with cardiac valvular heart disease

NCT00359489
Pfizer
Completed
Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Psoriatic Arthritis, Psoriasis, Papulosquamous Skin Diseases
NCT00293709
All Genders
18+
Years
Muenchen,
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
NCT02539368
All Genders
18+
Years
Multiple Sites
Erectile Dysfunction, Cardiovascular Diseases, Male Urogenital Diseases
NCT01150903
Males
Heart Valve Diseases
NCT00359489
All Genders
18+
Years
New Haven, Connecticut
Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.
A Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects
Methods study to evaluate use of cardiac ultrasound to assess heart valve abnormality in people.
Not Provided
Observational
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Heart Valve Diseases
Device: cardiac echosonography
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
July 2007
Not Provided

Inclusion Criteria:

  • >=18 years of age subjects with stable concomitant diseases with BMI >=30 kg/m2

Exclusion Criteria:

  • Pregnant females
  • Those with unstable/new onset diseases
  • Those who are on agents known to be associated with cardiac valvular heart disease
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00359489
A9001336
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now